2-amino-5-phosphonovalerate has been researched along with Absence Seizure Disorder in 8 studies
2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Strauss, U | 1 |
| Kole, MH | 1 |
| Bräuer, AU | 1 |
| Pahnke, J | 1 |
| Bajorat, R | 1 |
| Rolfs, A | 1 |
| Nitsch, R | 1 |
| Deisz, RA | 2 |
| Badiu, CI | 1 |
| Avanzini, G | 1 |
| de Curtis, M | 1 |
| Franceschetti, S | 1 |
| Sancini, G | 1 |
| Spreafico, R | 1 |
| Chrobok, L | 1 |
| Palus, K | 1 |
| Jeczmien-Lazur, JS | 1 |
| Chrzanowska, A | 1 |
| Kepczynski, M | 1 |
| Lewandowski, MH | 1 |
| Stewart, LS | 1 |
| Wu, Y | 1 |
| Eubanks, JH | 1 |
| Han, H | 1 |
| Leschenko, Y | 1 |
| Perez Velazquez, JL | 1 |
| Cortez, MA | 1 |
| Snead, OC | 1 |
| Lacey, CJ | 1 |
| Bryant, A | 1 |
| Brill, J | 1 |
| Huguenard, JR | 1 |
| Sasaki, S | 1 |
| Huda, K | 1 |
| Inoue, T | 1 |
| Miyata, M | 1 |
| Imoto, K | 1 |
8 other studies available for 2-amino-5-phosphonovalerate and Absence Seizure Disorder
| Article | Year |
|---|---|
An impaired neocortical Ih is associated with enhanced excitability and absence epilepsy.
Topics: 2-Amino-5-phosphonovalerate; Animals; Blotting, Western; Brain; Disease Models, Animal; Dose-Respons | 2004 |
Sensitivity of thalamic GABAergic currents to clonazepam does not differ between control and genetic absence epilepsy rats.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Animals; Antic | 2004 |
Cortical versus thalamic mechanisms underlying spike and wave discharges in GAERS.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Cerebral Cortex; Disease | 1996 |
The GABA(B) receptor antagonist CGP 55845A reduces presynaptic GABA(B) actions in neocortical neurons of the rat in vitro.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Animals; Delta | 1999 |
Disinhibition of the intergeniculate leaflet network in the WAG/Rij rat model of absence epilepsy.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Age Factors; Animals; Animals, Newborn; Disease Models, Animal | 2017 |
Severity of atypical absence phenotype in GABAB transgenic mice is subunit specific.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Animals, Newborn; Autoradiography; Cognition Disorder | 2009 |
Enhanced NMDA receptor-dependent thalamic excitation and network oscillations in stargazer mice.
Topics: Action Potentials; Animals; Biophysical Phenomena; Calcium Channels; Disease Models, Animal; Electri | 2012 |
Impaired feedforward inhibition of the thalamocortical projection in epileptic Ca2+ channel mutant mice, tottering.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Afferent Pathways; Age Factors; Animals; Calcium Channel Block | 2006 |